InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,084.75
(
0.72%
)
US TECH 100
17,102.80
(
0.74%
)
Dow Jones
38,190.66
(
0.28%
)
Brent Oil
88.42
(
0.30%
)
Bitcoin
64,065.59
(
-0.65%
)
Post# of 2795
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Warchest

Send PM Follow Ignore
Followers 4205
Posts 94790
Boards Moderated 0
Alias Born 01/19/2010

Warchest

Re: None

Tuesday, 11/17/2015 10:12:58 AM

Tuesday, November 17, 2015 10:12:58 AM

Post# of 2795
announced positive results from the Company's Phase 1 study of the oral formulation of OCR-002, ornithine phenylacetate, in healthy subjects. OCR-002 exhibited encouraging extended-release properties, demonstrated a desirable pharmacokinetic (PK) profile and was well-tolerated.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up